PUBLISHER: The Business Research Company | PRODUCT CODE: 1672322
PUBLISHER: The Business Research Company | PRODUCT CODE: 1672322
Biotechnology services involve the modification of living microorganisms to produce customized biotechnology products for medical, pharmaceutical, and scientific laboratories on a contract or custom basis. These services contribute to the development of breakthrough products and technologies aimed at addressing diseases, environmental concerns, hunger, energy efficiency, and cleaner industrial processes.
Key types of biotechnology services include prevention and disease control, public engagement activities, health education and research, food biotechnology services, donor recruitment, tissue collection, cell processing and isolation, and research and development. Food biotechnology services cover various technologies applied in crops, livestock, forestry, fisheries, aquaculture, and agro-industry. These services are utilized for genetic improvement, conservation of genetic resources, disease diagnosis, vaccine development, and fermented food production. Applications of biotechnology services span the pharmaceutical, biotechnological, academic, clinical trial, and healthcare sectors, with usage by Clinical Research Organizations (CROs), Contract Manufacturers Organizations (CMOs), and Contract Research and Manufacturing Services (CRAMS).
The biotechnology services market research report is one of a series of new reports from The Business Research Company that provides biotechnology services market statistics, including biotechnology services industry global market size, regional shares, competitors with a biotechnology services market share, detailed biotechnology services market segments, market trends and opportunities, and any further data you may need to thrive in the biotechnology services industry. This biotechnology services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The biotechnology services market size has grown steadily in recent years. It will grow from $133.74 billion in 2024 to $140.24 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to strong economic growth in emerging markets, increased collaborations with other research institutes and companies, and increased demand for food.
The biotechnology services market size is expected to see strong growth in the next few years. It will grow to $171.87 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to the rapid advancements in technology, rising non-communicable diseases, emphasis on innovation, rising demand for agriculture-based biotechnology services, growing demand for synthetic biology, developments and improvements in drug research, growth in personalized treatment, and collaboration and partnership. Major trends in the forecast period include strategic collaborations, integrating data management systems through cloud technology, development of next-generation sequencing technology, adapting digitalizing techniques in conducting clinical trials, implementing automated solutions, deploying artificial intelligence technologies, and investment in synthetic biology to develop products and solutions.
The growing prevalence of conditions such as hepatitis B, diabetes, and cancer is fueling biotechnology research. Biotechnology utilizes research tools from biology and chemistry to examine the genetic material of bacteria and viruses to identify disease-causing agents. Among biopharma companies, oncology research stands out as the most significant focus. Advances in medical applications include stem cell treatments utilizing monoclonal antibodies and genome sequencing. For example, in June 2024, the National Health Service (NHS), a UK-based government department, reported that in 2023, it identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, raising the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a general practitioner (GP) to 3,615,330. This marks a notable increase from 3,065,825 in 2022, reflecting a rise of nearly 20%. Additionally, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, projected that by 2050, there would be over 35 million new cancer cases, representing a 77% increase compared to an estimated 20 million cases in 2022. Consequently, the rising prevalence of diseases and significant investments in R&D are expected to drive growth in the biotechnology services market.
The escalating demand for clinical solutions catering to chronic disease treatments is set to be a significant driver for the expansion of the biotechnology services market. Chronic diseases encompass enduring medical conditions persisting for an extended duration, typically three months or more. Biotechnology services play a pivotal role in offering innovative clinical solutions for managing chronic diseases, including advanced therapies, precision medicine, and targeted treatments personalized to individual patients. These advancements significantly enhance the management and outcomes of chronic ailments. For instance, as per the World Health Organization (WHO) in September 2022, chronic diseases account for 74% of global deaths, amounting to 41 million fatalities annually. This includes 17.9 million deaths attributed to cardiovascular diseases, 9.3 million to cancer, 4.1 million to chronic respiratory diseases, and 2.0 million to diabetes. Hence, the mounting demand for clinical solutions tailored to chronic disease treatment is a driving force behind the growth of the biotechnology services market.
Collaborations and partnerships among industry players are increasingly becoming a trend in the biotech services sector. For example, in April 2024, ICL Partners, an Israel-based manufacturing company, joined forces with Ideelab Biotechnology, a Brazil-based biotechnology firm, to expedite the development of innovative biological technologies for agriculture, with an emphasis on sustainable and regenerative solutions. By harnessing Ideelab's expertise in advanced biologicals alongside ICL's leadership in plant nutrition and physiology, the partnership aims to develop next-generation products that tackle global agricultural challenges and improve food production.
Key companies within the biotechnology services market are dedicated to pioneering innovative therapies, such as biomarker algorithms for the primary treatment of patients with non-small cell lung cancer (NSCLC). Biomarker algorithms encompass mathematical or computational models integrating data from multiple biological indicators to provide comprehensive assessments of specific medical conditions. For instance, in April 2023, Strata Oncology Inc., a US-based precision oncology company, introduced Strata Select-a groundbreaking molecular profiling test for advanced cancer patients. Noteworthy for being the first immunotherapy biomarker algorithm covered by Medicare across solid tumors, Strata Select empowers oncologists to make more informed treatment decisions, thereby enhancing patient outcomes.
In December 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired POINT Biopharma Global Inc. for an undisclosed sum. This strategic acquisition aims to enhance Lilly's oncology expertise, particularly in advanced radioligand therapies designed to treat various forms of cancer. POINT Biopharma Global Inc. is a US-based biotechnology company recognized for its innovative methods in cancer treatment.
Major companies operating in the biotechnology services market include Parexel International Corporation, Thermo Fisher Scientific, Laboratory Corporation of America Holdings, IQVIA, ICON plc, Charles River Laboratories, Syneos Health, Sartorius AG, Precision for Medicine Inc., Novartis, Eppendorf Asia Pacific Sdn. Bhd., Emmessar Biotech & Nutrition Ltd, Vcanbio Cell & Gene Engineering Corp., Ltd, Ke Rui Gene, Absea Biotechnology Ltd, CStone Pharm-B, Daiichi Sankyo, bitBiome, Taisho Pharmaceutical, AGC Biologics, Hamamatsu Pharma Research, Artios Pharma, AstraZeneca, Bio Products Laboratory (BPL), Cambridge Bioscience, Shire Pharmaceuticals Ltd, BTG Ltd, eXmoor Pharma, 4D Pharma PLC, Touchlight Genetics, Ophidia Medical Technologies, ATAI Life Sciences, Phaseform, Evotec, Sanity Group, Primmbiotech Vaccitech, Biolat, Asla-Biotech, Genera, Anima Lab, Silvanols, OU TBD-Biodiscovery, Qvalitas Arstikeskus AS, Concise Systems OU, GPE Globalpharma OU, Belarusian National Biotechnology Corporation, Innothera, Olainfarm, Pharmaidea, Amgen Inc., Gilead Sciences, Celgene Corporation, Biogen Inc., Vertex Pharmaceuticals, Illumina, Inc., Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals, Hemostemix Inc., Resverlogix Corporation, Zenith Epigenetics Corp., Bayer, AMEGA Biotech, Pierre Fabre, Pfizer, Quantificare, Apsen Farmaceutica, BioMarin Pharmaceutical, DK Diagnostics, Biosonda Biotechnology, Laboratorios Legrand, Biomerics, Julphar Pharmaceuticals, Medpharma, Pharmax, Neopharma, City Breeze Technical Services, CinnaGen, BioSun Pharmed, AryoGen Pharmed, 4Clinics, 54gene, Amoun, Aspen Pharmacare, BBI Solutions, BioTech Africa, ClinArt MENA, Crux Pharmaceuticals, Genesis Pharmaceuticals, Massive Genomics, Mayne Pharma, Sanofi Genzyme, Teleflex Medical, The Micron Group
Asia-Pacific was the largest region in the biotechnology services market in 2024. North America was the second largest region in the global biotechnology services market analysis. The regions covered in the biotechnology services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the biotechnology services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain
The biotechnology services market consists of revenue earned by entities that engage in conducting research and experimental development in biotechnology. Numerous global issues are helped by biotechnology, including infectious diseases, ageing societies, food security, energy security, and climate change, to name a few. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Biotechnology Services Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on biotechnology services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for biotechnology services ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biotechnology services market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.